Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

• Published in: The New England journal of medicine Vol. 389; no. 3; pp. 228 - 238
• Main Authors: Desai, Akshay S., Webb, David J., Taubel, Jorg, Casey, Sarah, Cheng, Yansong, Robbie, Gabriel J., Foster, Don, Huang, Stephen A., Rhyee, Sean, Sweetser, Marianne T., Bakris, George L.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 20.07.2023
• Subjects: Angiotensin; Angiotensinogen; Angiotensinogen - blood; Angiotensinogen - metabolism; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; Antihypertensive Agents - pharmacokinetics; Antihypertensive Agents - therapeutic use; Antihypertensives; Blood pressure; Blood Pressure - drug effects; Blood Pressure - physiology; Blood Pressure Monitoring, Ambulatory; Cardiology; Diet; Double-Blind Method; Enzymes; Genetics; Genetics General; Humans; Hyperkalemia; Hypertension; Hypertension - blood; Hypertension - drug therapy; Hypertension - etiology; Hypertension - metabolism; Hypotension; Hypothesis testing; Injections, Subcutaneous; Irbesartan - administration & dosage; Irbesartan - adverse effects; Irbesartan - pharmacokinetics; Irbesartan - therapeutic use; Nutrient deficiency; Pharmacists; Pharmacodynamics; Pharmacokinetics; Renal function; Research ethics; RNA Interference; RNA Therapeutics; RNA-mediated interference; Salt; Tetrazoles; United Kingdom > UK
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2208391

In this phase 1 study involving persons with hypertension, zilebesiran (an RNA interference therapeutic agent) was associated with decreases in angiotensin levels and systolic and diastolic blood pressure.